Cambridge Enterprise Venture Partners Dinner

The Cambridge Enterprise Ventures team are responsible for venture investing University of Cambridge funds into University of Cambridge spin-outs. The team invest in opportunities across the breadth of University research including quantum, silicon, sustainability, AI, med tech and drug discovery.

Christine’s background is in Life Science investment with a focus on drug discovery. She has supported numerous University of Cambridge spin-outs, including Carrick, Pretzel, Transition Bio, Z-factor, PhoreMost, Qkine, Spirea and Pharmenable.

52 North is reinventing the healthcare journey, creating affordable, cutting-edge technology to bring healthcare closer to patients.

Point of Contact: Amanda Wooding

Academic founders: Umaima Malik-Ahmad, Saif Ahmad, Fahad Ali

Visit the website

NoBACZ Healthcare is a company that specialises in sustainable, rapid-setting flexible barrier dressings for veterinary and human use, utilising a patented natural polymer to provide waterproof, antimicrobial protection.

Point of Contact: Amanda Wooding

Academic founders: Jonathan Powell, Nuno Faria

Visit the website

Paragraf is a company that mass produces graphene-based electronic devices using standard semiconductor processes for applications in automotive, healthcare, and quantum computing.

Point of Contact: Christine Martin

Academic founders: Simon Thomas, Ivor Guiney, Colin Humphreys

Visit the website

Carbon Re is an AI and climate tech software solution provider for glass, cement and other energy-intensive industries.

Point of Contact: Chris Gibbs

Academic founders: Daniel Summerbell, Buffy Price, Aidan O’Sullivan, Sherif Elsayed-Ali

Visit the website

Concrete is the second most used material on earth, behind only water. Cement is the binding agent used in concrete, and its production is responsible for 8% of global CO2 emissions. Cambridge Electric Cement (CEC) has developed a technology for recovering and reusing cement from demolition waste making zero carbon cement a possibility.

Point of Contact: Chris Gibbs

Academic founders: Bill Yost, Poppy Brewer, Dr Cyrille Dunant

Visit the website

Dr Glasheen has over 25 years of experience across industry and university environments in both Silicon Valley and the Cambridge Massachusetts innovation ecosystem. Most recently he was Co-founder and President of two biotech companies, Atalanta Therapeutics and Clade Therapeutics.

He also served as Executive Vice Chancellor – Innovation and Business Development at UMASS Medical School. He has extensive venture investment experience as General Partner and Life-Science Co-Lead at Palo Alto based firm Technology Partners Venture Capital. Dr Glasheen completed a post-doctoral fellowship at University of California, Berkeley and holds a PhD in Biology from Harvard University, a Deutscher Akademischer Austauschdienst Fellowship at Universität des Saarlandes and a BS from Duke University.